These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 25727705)
1. A new era for chagas disease drug discovery? Keenan M; Chaplin JH Prog Med Chem; 2015; 54():185-230. PubMed ID: 25727705 [TBL] [Abstract][Full Text] [Related]
2. Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease. Riley J; Brand S; Voice M; Caballero I; Calvo D; Read KD PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004014. PubMed ID: 26394211 [TBL] [Abstract][Full Text] [Related]
3. Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity. Hargrove TY; Wawrzak Z; Alexander PW; Chaplin JH; Keenan M; Charman SA; Perez CJ; Waterman MR; Chatelain E; Lepesheva GI J Biol Chem; 2013 Nov; 288(44):31602-15. PubMed ID: 24047900 [TBL] [Abstract][Full Text] [Related]
4. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease. Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982 [TBL] [Abstract][Full Text] [Related]
5. Chagas disease drug discovery: toward a new era. Chatelain E J Biomol Screen; 2015 Jan; 20(1):22-35. PubMed ID: 25245987 [TBL] [Abstract][Full Text] [Related]
6. Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity. Franco CH; Warhurst DC; Bhattacharyya T; Au HYA; Le H; Giardini MA; Pascoalino BS; Torrecilhas AC; Romera LMD; Madeira RP; Schenkman S; Freitas-Junior LH; Chatelain E; Miles MA; Moraes CB Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():107-120. PubMed ID: 32688218 [TBL] [Abstract][Full Text] [Related]
7. Design or screening of drugs for the treatment of Chagas disease: what shows the most promise? Lepesheva GI Expert Opin Drug Discov; 2013 Dec; 8(12):1479-89. PubMed ID: 24079515 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Buckner FS; Bahia MT; Suryadevara PK; White KL; Shackleford DM; Chennamaneni NK; Hulverson MA; Laydbak JU; Chatelain E; Scandale I; Verlinde CL; Charman SA; Lepesheva GI; Gelb MH Antimicrob Agents Chemother; 2012 Sep; 56(9):4914-21. PubMed ID: 22777048 [TBL] [Abstract][Full Text] [Related]
9. Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration. Ferreira de Almeida Fiuza L; Peres RB; Simões-Silva MR; da Silva PB; Batista DDGJ; da Silva CF; Nefertiti Silva da Gama A; Krishna Reddy TR; Soeiro MNC Eur J Med Chem; 2018 Apr; 149():257-268. PubMed ID: 29501946 [TBL] [Abstract][Full Text] [Related]
11. Phenotypic screening approaches for Chagas disease drug discovery. Chatelain E; Ioset JR Expert Opin Drug Discov; 2018 Feb; 13(2):141-153. PubMed ID: 29235363 [TBL] [Abstract][Full Text] [Related]
12. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034 [TBL] [Abstract][Full Text] [Related]
13. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Urbina JA Acta Trop; 2010; 115(1-2):55-68. PubMed ID: 19900395 [TBL] [Abstract][Full Text] [Related]
20. A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Olivieri BP; Molina JT; de Castro SL; Pereira MC; Calvet CM; Urbina JA; Araújo-Jorge TC Int J Antimicrob Agents; 2010 Jul; 36(1):79-83. PubMed ID: 20452188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]